Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) announced a strategic expansion of its intellectual property portfolio on February 18, 2026, following USPTO Notices of Allowance for multiple patent applications expected to issue in 2026. The company reported a portfolio of 29 issued U.S. patents, 9 international patents, and 31 pending applications.
Tenon also cited its recent asset acquisition of SIVantage's SImmetry and SImmetry+ systems, supported by 16 issued U.S. patents, which the company says complements the Catamaran platform and strengthens protection for its sacro-pelvic fusion technologies.
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET. The company provided revenue ranges: Q4 2025 $1.45–$1.48M (~90% YoY) and FY2025 $3.91–$3.94M (~20% YoY). Dial‑in, international numbers, webcast details, and replay access through April 2, 2026 were provided, with telephone replay access code 13758268.
Tenon (NASDAQ:TNON) reported preliminary, unaudited Q4 2025 revenue of $1.45–$1.48 million (~90% YoY) and full year 2025 revenue of $3.91–$3.94 million (~20% YoY). The company highlighted the SiVantage acquisition, FDA clearance for an expanded Catamaran indication, strong MAINSAIL 12-month fusion results (83% fusion), and plans to report audited results in March 2026.
Tenon Medical (NASDAQ:TNON) announced completion of initial clinical procedures using its new SImmetry+ SI Joint Fusion System on December 4, 2025, with cases at Centers of Excellence in Florida, Arizona, Ohio, and Texas.
The minimally invasive lateral system uses 3D-printed titanium implants, joint decortication, and a bone graft delivery system, cleared for use with one to three implants. Tenon cites published 12-month EvoluSIon data (250 patients): 68.7% radiographic fusion at 12 months and a 57.1% decrease in pre-operative opioid use.
Tenon is conducting a controlled early-access rollout with select SI fusion physicians to gather procedural feedback ahead of broader commercial launch.
Tenon Medical (NASDAQ:TNON) announced the closing of an at-the-market PIPE financing on November 14, 2025 that generated approximately $2.85 million in gross proceeds.
The company issued 2,217,904 shares of common stock and issued warrants to purchase an equal number of shares; each share-plus-warrant was sold at a combined price of $1.285. The PIPE Warrants carry a $1.16 exercise price and expire three years from issuance. Proceeds are intended for working capital, upcoming product launches, commercial expansion, clinical studies, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) reported Q3 2025 revenue of $1.2M, a 32% year-over-year increase driven by record Catamaran procedure volumes and the addition of SImmetry product sales. Gross profit was $773K with a 66% gross margin, up from 47% a year earlier. Q3 net loss was $3.3M (‑$0.40 per share). Cash and cash equivalents were $3.4M at September 30, 2025, and subsequent to quarter end the company raised $2.85M in PIPE financing. Tenon completed the SiVantage acquisition, expanded commercial training (26 physicians trained), and launched Catamaran SE and SImmetry+ activity to broaden its multi-product SI fusion portfolio.
Tenon Medical (NASDAQ:TNON) announced an at-the-market PIPE financing priced on November 11, 2025 to raise gross proceeds of $2,850,000. Under securities purchase agreements dated September 10, 2025, the company will issue 2,217,904 shares of common stock and warrants to purchase 2,217,904 shares at a combined offering price of $1.285 per share plus warrant. The PIPE warrants carry a $1.16 strike price and expire three years from issuance. The Issued Shares and warrant shares will have customary resale registration rights. Closing is subject to customary conditions. Tenon intends to use proceeds for working capital, product launches, commercial expansion, clinical studies, and core operations.
Tenon Medical (NASDAQ:TNON) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. The company will host a conference call the same day at 4:30 p.m. Eastern Time to discuss results and hold a Q&A with covering analysts.
Dial-in details: US 1-877-407-0792, Int'l 1-201-689-8263. Webcast available via the TNON conference call link. Audio playback will be available through November 27, 2025 on Tenon’s investor relations site or by telephone replay (1-844-512-2921 US; 1-412-317-6671 Int'l) using access code 13756541.
Tenon Medical (NASDAQ:TNON) announced FDA 510(k) clearance for the SImmetry+ SI Joint Fusion System on October 21, 2025. The minimally invasive lateral-access system uses new 3D-printed titanium implants, joint decortication, bone graft delivery, and fixation to enable SI joint fusion. Tenon plans an alpha launch targeting year-end 2025 with select physician users to gather initial feedback ahead of broader commercial rollout. SImmetry+ joins Tenon's Catamaran platform, expanding multi-approach SI fusion options supported by published prospective studies.
Tenon Medical (NASDAQ:TNON) announced compelling 12-month results from its MAINSAIL™ study evaluating the Catamaran® SI Joint Fusion System. The study showed significant clinical improvements, with pain scores (VAS) decreasing from 78.8mm to 23.0mm and disability scores (ODI) improving from 51.6% to 20.8%. 83% of patients demonstrated unequivocal fusion evidence at 12 months.
The study, involving 24 patients across six U.S. clinical sites, reported no serious adverse events and high patient satisfaction, with 83.3% reporting satisfaction at 12 months. The surgical efficiency was notable, with 45.7% of procedures completed in under 45 minutes. These results exceed average improvements reported in previous literature for SI joint fusion procedures.